Initial Public Offering (IPO)

DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. 

DanCann Pharma is a Danish public limited company incorporated in Denmark and operating under Danish law. The Issuer was founded on 20 March 2018 by CEO Jeppe Krog Rasmussen.

Description of DanCann Pharma as of 30 September 2020 see Prospectus below.

More information about DanCann Pharma is available under Presentations or in the IPO Teasers.  

Subscriptions can be made through any of the following platforms:

 

Summary of the offer

The Company offers “Units”. One (1) Unit consists of 5 Shares and 2 Warrants in the Company.

Subscription period:
7 October  2020 to 23 October 2020

Subscription price:
DKK 22.50 per Unit. One (1) Unit consists of five (5) Shares of DKK 4.50 each and two (2) Warrants (series TO 1) free of payment.

Minimum subscription:
The minimum subscription is 200 Units (for each subscriber), corresponding to DKK 4,500.

Subscription commitments:
The Company has received subscription commitments of approximately DKK 22.5 million, a total of approximately 75 per cent of the issue of Units.

Number of Shares in the Company before the issue of Units: 14,060,800 Shares

Valuation (pre-money): Approximately DKK 63.3 million.

Listing on Spotlight Stock Market: DanCann Pharma’s Shares and Warrants are planned to be listed on Spotlight Stock Market. The first day of trading is projected to be on 12 November 2020.

Ticker, ISIN: DANCAN, ISIN code DK0061410487. DANCAN TO 1, ISIN code DK0061410560.